Stephen K. Brannan - 09 Dec 2022 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Medical Officer
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 09 Dec 2022
Net transactions value: -$964,819
Form type: 4
Filing time: 12 Dec 2022, 16:04:52 UTC
Previous filing: 10 Nov 2022
Next filing: 09 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$26,441	+3,637	+24%	$7.27^*	18,637	09 Dec 2022	Direct
transaction	KRTX	Common Stock	Sale	$730,164	-3,637	-20%	$200.76	15,000	09 Dec 2022	Direct	F1
transaction	KRTX	Common Stock	Options Exercise	$12,540	+1,363	+9.1%	$9.20^*	16,363	09 Dec 2022	Direct
transaction	KRTX	Common Stock	Sale	$273,636	-1,363	-8.3%	$200.76	15,000	09 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-3,637	-51%	$0.000000	3,473	09 Dec 2022	Common Stock	3,637	$7.27	Direct	F2
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-1,363	-11%	$0.000000	11,362	09 Dec 2022	Common Stock	1,363	$9.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2	This option vested as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of August 8, 2018.
F3	This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.